Study finds that generic drugs suffer more recalls

Researchers from three universities, including Indiana University, have found that price competition in the generic drug market might be putting more patients at health risk due to a higher number of manufacturing-related product recalls.

Promoting the availability of more affordable medication “has some unexpected risks that regulators and lawmakers may not have foreseen when pushing for cheaper drugs,” George Ball, assistant professor of operations and decision technologies at the Indiana University Kelley School of Business and the study’s lead author, said in a written statement.•

Please enable JavaScript to view this content.

Story Continues Below

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our updated comment policy that will govern how comments are moderated.

{{ articles_remaining }}
Free {{ article_text }} Remaining
{{ articles_remaining }}
Free {{ article_text }} Remaining Article limit resets in {{ count_down }} days.